in

U.S. FDA approves Amgen’s biosimilar version of J&J’s psoriasis drug

Despite the FDA approval, Amgen’s treatment is expected to be launched in 2025 as part of a legal settlement between the two companies earlier this year to delay the entry of the therapy.

Biosimilars are close copies of complex biological drugs.

Stelara, introduced in 2009, has been J&J’s top-selling drug since 2019, with sales reaching $9.7 billion in 2022.


Source: Economy - investing.com

New Zealand jobless rate climbs in Q3, market sees end to rate hikes

Bitget, Floki teams accuse each other of manipulation after token listing